Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2026)
Vivos Therapeutics (VVOS) reported Income from Continuing Operations of 7751000.0 for Q1 2026, down 100.6% year-over-year from 1302168000.0 in Q1 2025, and down 11.46% quarter-over-quarter from 6954000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Income from Continuing Operations data on file, last reported at 7751000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 7751000.0, down 100.6% year-over-year; the trailing twelve-month figure through Mar 2026 was 25118000.0 (down 122.38% YoY), and the FY2025 annual result was 21230000.0, down 89.66% from the prior year.
- Income from Continuing Operations declined to 7751000.0 in Q1 2026 per VVOS's latest filing, from 6954000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9367000.0 in Q4 2023 and troughed at 7751000.0 in Q1 2026.
- A 5-year average of 3763470.59 and a median of 5013000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations surged 253.83% in 2023, then slumped 159.74% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6089000.0 in 2022, then surged by 253.83% to 9367000.0 in 2023, then tumbled by 130.8% to 2885000.0 in 2024, then sank by 141.04% to 6954000.0 in 2025, then declined by 11.46% to 7751000.0 in 2026.
- Business Quant data shows VVOS's Income from Continuing Operations at 7751000.0 in Q1 2026, 6954000.0 in Q4 2025, and 5400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 273.95 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 220.30 Mn |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -7.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -3.76 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -5.53 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | -7.41 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.04 Mn |